GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pulmatrix Inc (NAS:PULM) » Definitions » Beneish M-Score

Pulmatrix (Pulmatrix) Beneish M-Score : -2.44 (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Pulmatrix Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.44 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Pulmatrix's Beneish M-Score or its related term are showing as below:

PULM' s Beneish M-Score Range Over the Past 10 Years
Min: -5.15   Med: -2.35   Max: 39.95
Current: -2.44

During the past 12 years, the highest Beneish M-Score of Pulmatrix was 39.95. The lowest was -5.15. And the median was -2.35.


Pulmatrix Beneish M-Score Historical Data

The historical data trend for Pulmatrix's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmatrix Beneish M-Score Chart

Pulmatrix Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.95 -2.26 -2.19 12.12 -2.44

Pulmatrix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.12 -2.25 -1.42 -1.53 -2.44

Competitive Comparison of Pulmatrix's Beneish M-Score

For the Biotechnology subindustry, Pulmatrix's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulmatrix's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pulmatrix's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Pulmatrix's Beneish M-Score falls into.



Pulmatrix Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Pulmatrix for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5947+0.528 * 1+0.404 * 1.068+0.892 * 1.2021+0.115 * 5.4443
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8002+4.679 * 0.062194-0.327 * 2.9384
=-2.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.93 Mil.
Revenue was 2.202 + 1.753 + 1.844 + 1.499 = $7.30 Mil.
Gross Profit was 2.202 + 1.753 + 1.844 + 1.499 = $7.30 Mil.
Total Current Assets was $20.84 Mil.
Total Assets was $33.96 Mil.
Property, Plant and Equipment(Net PPE) was $11.47 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.48 Mil.
Selling, General, & Admin. Expense(SGA) was $6.52 Mil.
Total Current Liabilities was $3.91 Mil.
Long-Term Debt & Capital Lease Obligation was $8.33 Mil.
Net Income was -2.083 + -3.774 + -3.816 + -4.448 = $-14.12 Mil.
Non Operating Income was -0.05 + -0.052 + -0.061 + -0.085 = $-0.25 Mil.
Cash Flow from Operations was -2.011 + -4.142 + -4.904 + -4.928 = $-15.99 Mil.
Total Receivables was $1.30 Mil.
Revenue was 1.708 + 1.872 + 1.331 + 1.16 = $6.07 Mil.
Gross Profit was 1.708 + 1.872 + 1.331 + 1.16 = $6.07 Mil.
Total Current Assets was $38.15 Mil.
Total Assets was $40.95 Mil.
Property, Plant and Equipment(Net PPE) was $0.95 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.55 Mil.
Selling, General, & Admin. Expense(SGA) was $6.78 Mil.
Total Current Liabilities was $5.02 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.928 / 7.298) / (1.298 / 6.071)
=0.127158 / 0.213803
=0.5947

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6.071 / 6.071) / (7.298 / 7.298)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (20.843 + 11.467) / 33.958) / (1 - (38.147 + 0.945) / 40.953)
=0.048531 / 0.045442
=1.068

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=7.298 / 6.071
=1.2021

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.545 / (1.545 + 0.945)) / (1.475 / (1.475 + 11.467))
=0.620482 / 0.11397
=5.4443

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6.52 / 7.298) / (6.778 / 6.071)
=0.893395 / 1.116455
=0.8002

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((8.327 + 3.909) / 33.958) / ((0 + 5.022) / 40.953)
=0.360327 / 0.122628
=2.9384

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-14.121 - -0.248 - -15.985) / 33.958
=0.062194

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Pulmatrix has a M-score of -2.44 suggests that the company is unlikely to be a manipulator.


Pulmatrix Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Pulmatrix's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulmatrix (Pulmatrix) Business Description

Traded in Other Exchanges
Address
99 Hayden Avenue, Suite 390, Lexington, MA, USA, 02421
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
Executives
Peter Ludlum officer: Interim CFO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Margaret Wasilewski officer: Chief Medical Officer C/O PULMATRIX, INC., 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Anand Varadan director C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Todd Bazemore director C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Christopher Cabell director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Michelle Siegert officer: Vice President, Finance 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Richard P. Batycky director C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Nelsen other: Former 10% owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Polaris Venture Partners Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Entrepreneurs' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Special Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Management Co. V, L.l.c. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Jonathan A Flint 10 percent owner 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Polaris Venture Management Co Iv Llc 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210

Pulmatrix (Pulmatrix) Headlines

From GuruFocus

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

By PRNewswire PRNewswire 03-17-2022